Patents by Inventor Sylvie Mader

Sylvie Mader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954194
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 23, 2021
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10752591
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 25, 2020
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389805
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20190389806
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Application
    Filed: July 3, 2019
    Publication date: December 26, 2019
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10377715
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 13, 2019
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10324085
    Abstract: Described herein is a bioluminescence resonance energy transfer (BRET) based system and method to monitor ternary complex formation in real-time in live cells with high sensitivity and accuracy. This system transfers energy simultaneously between a luciferase donor and intermediate and terminal acceptors, appropriately chosen to also enable transfer from the intermediate to terminal acceptor while minimizing contaminating signals. The system may also be adapted for quaternary complex detection by including a protein complementation assay (PCA) component. The system is broadly applicable to the detection of any protein ternary/quaternary complex such as those involving nuclear receptors, GPCRs, Receptor Tyrosine Kinase (RTKs), multimeric enzymes or structural proteins.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 18, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: David Cotnoir-White, Sylvie Mader, Étienne Gagnon, Michel Bouvier
  • Publication number: 20180362467
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: December 6, 2017
    Publication date: December 20, 2018
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20170114019
    Abstract: The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors; promoting muscle formation; inhibiting muscle degeneration or the loss of muscle mass or muscle function; and myofibers ex vivo.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 27, 2017
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20170038367
    Abstract: Described herein is a bioluminescence resonance energy transfer (BRET) based system and method to monitor ternary complex formation in real-time in live cells with high sensitivity and accuracy. This system transfers energy simultaneously between a luciferase donor and intermediate and terminal acceptors, appropriately chosen to also enable transfer from the intermediate to terminal acceptor while minimizing contaminating signals. The system may also be adapted for quaternary complex detection by including a protein complementation assay (PCA) component. The system is broadly applicable to the detection of any protein ternary/quaternary complex such as those involving nuclear receptors, GPCRs, Receptor Tyrosine Kinase (RTKs), multimeric enzymes or structural proteins.
    Type: Application
    Filed: December 23, 2014
    Publication date: February 9, 2017
    Inventors: DAVID COTNOIR-WHITE, SYLVIE MADER, ÉTIENNE GAGNON, MICHEL BOUVIER
  • Publication number: 20140051760
    Abstract: Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses HDAC activity while maintaining RAR agonist activity. Hybrid molecule 3 and pharmaceutical compositions thereof can be used in the treatment of breast cancer, leukemia, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and cancer of the CNS.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 20, 2014
    Applicants: Universite de Montreal, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Wilson H. Miller, James Gleason, Sylvie Mader
  • Publication number: 20130165520
    Abstract: Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (HDAC) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses HDAC activity while maintaining RAR agonist activity. Hybrid molecule 3 and pharmaceutical compositions thereof can be used in the treatment of breast cancer, leukemia, non-small cell lung cancer, colon cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and cancer of the CNS.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 27, 2013
    Applicants: UNIVERSITY DE MONTREAL, THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Wilson H. Miller, Sylvie Mader, James Gleason
  • Publication number: 20030031650
    Abstract: The present invention relates to a drug inducible vector regulatable with a transactivator native to a host, and to a transplantable autologous tissue capable of engrafting in a recipient without requiring toxic conditioning, for transgene delivery to a recipient. Current drug inducible host-vector systems are responsible to foreign non-eukaryotic transcriptional activators which are potentially immunogenic and affect the long-term survival and function thereof. The present invention provides a drug inducible expression vector comprising a transgene operably linked to a reporter and to an inducible promoter responsive to a transcriptional activator of a host when exposed to an effective amount of a clinically acceptable drug.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 13, 2003
    Inventors: Jacques Galipeau, Diane E. Jaalouk, Nicoletta Eliopoulos, Clement Couture, Sylvie Mader
  • Patent number: 5512483
    Abstract: Expression vector adapted for expression of cloned genes in an animal cell comprising a steroid responsive promoter, the promoter consisting essentially of a plurality of glucocorticoid response elements (GREs), a TATA box, and an initiator element containing a transcriptional initiator site located from 20 to 50 bases from the TATA box, the promoter lacking upstream elements which bind nuclear factor I, and the vector further comprising a restriction endonuclease site downstream from the promoter for insertion of DNA to be expressed from the promoter, wherein the DNA is expressed from the vector in an animal cell.
    Type: Grant
    Filed: May 21, 1993
    Date of Patent: April 30, 1996
    Assignee: McGill University
    Inventors: Sylvie Mader, John H. White